Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

Sang Hoon Ahn, Patrick Marcellin, Xiaoli Ma, Florin A. Caruntu, Won Young Tak, Magdy Elkhashab, Wan Long Chuang, Fehmi Tabak, Rajiv Mehta, Jörg Petersen, William Guyer, Belinda Jump, Alain Chan, Mani Subramanian, Gerald Crans, Scott Fung, Maria Buti, Giovanni B. Gaeta, Aric J. Hui, George PapatheodoridisRobert Flisiak, Henry L.Y. Chan

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


Background and Aims: Hepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during oral antiviral treatment. A current unmet need in CHB management is achievement of HBsAg loss with a finite course of oral antiviral therapy, thereby allowing discontinuation of treatment. Significantly higher rates of HBsAg loss at 72 weeks post-treatment have been demonstrated when tenofovir disoproxil fumarate (TDF) was combined with pegylated interferon (PEG-IFN) for 48 weeks compared with either monotherapy. This analysis provides follow-up data at week 120. Methods: In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus PEG-IFN for 48 weeks (group A), TDF plus PEG-IFN for 16 weeks followed by TDF for 32 weeks (group B), TDF for 120 weeks (group C), or PEG-IFN for 48 weeks (group D). Efficacy and safety at week 120 were assessed. Results: Rates of HBsAg loss at week 120 were significantly higher in group A (10.4%) than in group B (3.5%), group C (0%), and group D (3.5%). Rates of HBsAg loss and HBsAg seroconversion in group A were significantly higher than rates in group C (P < 0.001 for both) or group D (HBsAg loss: P = 0.002; HBsAg seroconversion: P < 0.001). Conclusions: The results of this analysis confirm the results from earlier time points which demonstrate the increased rate of HBsAg loss in patients treated with a finite course of PEG-IFN plus TDF compared with the rates in patients receiving either monotherapy.

Original languageEnglish
Pages (from-to)3487-3497
Number of pages11
JournalDigestive diseases and sciences
Issue number12
Publication statusPublished - 2018 Dec 1

Bibliographical note

Publisher Copyright:
© 2018, The Author(s).

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology


Dive into the research topics of 'Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis'. Together they form a unique fingerprint.

Cite this